Sustainability Highlights & ESG Performance

• R&D for Products and Innovation: Cell therapy R&D has progressed to the clinical trial stage; the total number of accumulated patents has reached 102.
• Integrity in Business and Corporate Governance: In 2024, there were no penalties or complaints related to corporate governance, anti-corruption, or regulatory compliance. The performance evaluation scores for the Board of Directors and all functional committees exceeded standards, each achieving over 90 points.
• Promoting Workplace Diversity: Women account for 37.5% of board members, and both female managers and female employees constitute more than half of the workforce.
• Strengthening Supply Chain Resilience: All supplier evaluations in 2024 achieved an A rating.
• Maintaining Customer Relationships: In 2024, there were no negative incidents related to customer relations, breaches of customer privacy, or customer complaints regarding product quality and safety.
• Promoting Energy Conservation and Carbon Reduction: Continued equipment audits, set plan for upgrades and replacements, promoted paperless operations and low-carbon lifestyles, improved energy efficiency, and reduced carbon emissions, moving toward carbon and waste reduction goals.
• Social Welfare Participation: Organized or participated in donation activities for disadvantaged groups, and collaborated with medical institutions to extend charitable care.

Operational Highlights

• For the oncolytic virus drug under development, OBP-301, Medigen entered into a sales partnership with the Japanese publicly traded company Oncolys BioPharma Inc. (Oncolys). Oncolys reached an agreement with Japan PMDA to initiate the “Pre-application Consultation,” which is expected to shorten the review process.
• Obtained an approval from Taiwan MOHW for the use of Medigen’s new version autologous Megicell-NK technology for produce NK cell for cell therapy at Taichung Tzu Chi Hospital in accordance with the regulations of the ”Regulations Governing the Application of Specific Medical Examination Technique and Medical Device.”
• Obtained an approval from the Taiwan Food and Drug Administration (TFDA) to conduct a Phase I /II clinical trial using allogeneic natural killer cells (Magicell®-NK).